{
  "id": 163707,
  "title": "Recombinant sialylated ApoE2 suppresses ApoE4 and sex-specifically strengthens brain metabolism and cognition in ApoE4 mice",
  "url": "https://urgent.news/2026/08/04/recombinant-sialylated-apoe2-suppresses-apoe4-and-sex-specifically",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-04T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.07.30.741628v1?rss=1"
  },
  "original_language": "en",
  "account": "A groundbreaking study explores the therapeutic potential of a sialylated form of human ApoE2 protein to protect and enhance brain metabolism and cognition in mice genetically predisposed to Alzheimer's disease. Researchers created a highly sialylated version of ApoE2, mimicking its natural presence in the human brain. When administered to ApoE4-knockin mouse neurons, the modified protein increased hexokinase 2 expression and reduced endogenous ApoE4 levels. It also shielded ApoE4 neurons from damage caused by toxic amyloid-beta and oxidative stress. To ensure safe delivery to the brain, researchers developed a peptide that temporarily increased the permeability of the blood-brain barrier. Weekly intravenous injections of the sialylated ApoE2, combined with the peptide, improved synapse function, lipid metabolism, and DHA utilization in the cortex of middle-aged and aged ApoE4 mice. Moreover, the findings indicate that the treatment strengthened cognitive abilities, with some improvements observed only in female mice. These results suggest that the sialylated human ApoE2 protein may hold promise as a therapeutic strategy to bolster brain metabolism and cognitive function in aging individuals at risk for Alzheimer's disease, with potential sex-specific benefits.",
  "summary": "Human APOE4 is the strongest genetic risk factor for late-onset Alzheimer's disease (AD), whereas the relatively rare APOE2 confers exceptional protection. This study examines whether recombinant ApoE2 protein can therapeutically leverage this genetic advantage to strengthen aging brains at risk for AD. We produced recombinant human ApoE2 (rhApoE2) using the FreeStyle 293-F system, yielding…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}